Research paperProfiling gene expression of whole cytochrome P450 superfamily in human bronchial and peripheral lung tissues: Differential expression in non-small cell lung cancers
Introduction
Lung is the primary site of exposure for inhaled chemical toxicants and carcinogens. Consequently, enzymes involved in the metabolism of xenobiotics and expressed at the pulmonary level play a major role in the protection of the organism. Among these xenobiotic-metabolizing enzymes (XMEs), cytochromes P450 (CYPs) are phase I (i.e. functionalization) enzymes that modify substrates directly via oxidation reactions. These biotransformations can be beneficial as they enable further conjugation by phase II enzymes and elimination from the organism; in other cases, depending on the substrate, these reactions can rather activate harmless procarcinogens into reactive intermediates capable of binding to DNA, leading to mutations and eventually to tumor initiation [1]. CYP enzymes are also involved in many endogenous pathways such as the metabolism of eicosanoids, the biosynthesis of bile acids and steroid hormones and the metabolism of vitamin D and retinoic acid. As they control the levels of these endogenous substrates which are sometimes associated with tumor promotion or progression, it could be stated that the CYP enzymes participate indirectly in tumorigenesis [2].
Many lung diseases, such as lung cancer and chronic obstructive pulmonary disease, are mostly due to environmental exposure to chemical compounds, the main ones being chemicals contained in tobacco smoke. However, there is increasing evidence that inherited genetic factors could be important additional risk determinants in lung disease pathogenesis [3]. To date, no major predisposition loci have been identified and it has been assumed that low-penetrance high-prevalence polymorphic genes may account for the majority of genetic susceptibility to lung diseases. Consequently, CYP genes are good candidates as many of them are highly polymorphic and can modulate total exposure to chemicals and carcinogens. Nebert and Dalton [2] proposed a two-tiered model to predict an overall inter-individual risk of developing cancer, based on variants in certain “early defence” CYP genes, combined with polymorphisms in various downstream target genes (i.e. proto-oncogenes, tumor-suppressor genes, genes that encode XME receptors or transcription factors).
Resistance to chemotherapy agents remains a major obstacle for successful treatment of many cancers and some non-small cell lung cancers (NSCLC) tend to be intrinsically resistant to chemotherapy. This intrinsic chemoresistance could be the result of enhanced inactivation of the drug or of failure to convert the prodrug to its active form by xenobiotic-metabolizing enzymes like CYPs [4]. Profiling CYP gene expression in cancer cells could allow a better understanding of the mechanisms that influence tumor response to anti-cancer drugs.
The expression profile of CYPs has previously been investigated in human lung, but pooled whole lung tissues were generally analyzed [5], [6], [7], [8], [9], [10], [11], [12], [13], [14], [15], [16], [17], [18], [19]. Thus little is known about the differences in the metabolic potential between individuals, as well as between the two distinct pulmonary compartments that are bronchial mucosa and pulmonary parenchyma. Moreover, to our knowledge, the 57 human CYP genes have never been studied simultaneously. Additionally, even though the expression of many CYPs has been investigated in NSCLC which is the predominant form of lung cancer throughout the world [10], [18], [19], [20], [21], [22], [23], [24], [25], [26], [27], [28], [29], [30], [31], [32], [33], [34], there is still a need for comprehensive analyses of all the human CYP genes in tumoral lung tissues.
The current study was undertaken to investigate the expression profile of the 57 human cytochrome P450 genes in non-tumoral and tumoral lung tissues, focusing on inter-individual variability and on the differences between distinct tissues. We used quantitative real-time RT-PCR (reverse transcription-polymerase chain reaction) with TaqMan low-density arrays (TLDA) to conduct this comprehensive analysis in non-tumoral bronchial mucosa and pulmonary parenchyma, as well as in tumoral tissues of patients with NSCLC.
Section snippets
Patients and samples
Eighteen patients undergoing partial or complete lung resection for non-small cell lung cancer (NSCLC) were included in this study. Half of these patients were suffering from adenocarcinoma (AC) and the others were suffering from squamous cell carcinoma (SCC). None of them were treated with preoperative radiotherapy or chemotherapy. Informations on age, sex, tumor histological type and TNM classification are listed in Table 1. All the patients were former smokers or smokers who stopped smoking
Results
In this study, quantitative real-time RT-PCR using TaqMan low-density arrays was used to determine the mRNA expression level of the 57 human cytochrome P450 and of the P450 oxidoreductase genes. We first performed a control RT(−) experiment with a pooled RNA sample to test specificity of the assays for the detection of mRNA. Only CYP2A7 assay gave a very faint signal (Ct above 36).
The expression profile of CYP genes was investigated in non-tumoral lung tissues (bronchial mucosa and pulmonary
Discussion
In this study, the mRNA expression profile of the 57 human cytochrome P450 genes in non-tumoral and tumoral lung tissues was investigated for the first time with a special focus on inter-individual variability and on the differences between distinct tissues. For this purpose we chose to use TaqMan low-density arrays (TLDA) that are based on quantitative real-time RT-PCR. Some of the CYP coding genes are clustered in the same chromosomal regions and their nucleotide sequences show considerable
Conclusion
This study represents an initial high throughput comprehensive characterization of CYP expression profile in the lung. Assessment of CYP protein levels and activity measurements will be necessary to further validate our results and confirm translation of mRNA into functional enzymes. For genes with low mRNA levels in lung tissues in particular, it can not be asserted that these mRNA will lead to meaningful enzyme activity.
This study provides insight into the inter-individual variability in lung
Acknowledgments
This study was supported by the Centre Hospitalier Régional et Universitaire (CHRU) de Lille, the Université de Lille 2, the Fonds européen de développement régional (FEDER), the Institut de Recherche en Environnement Industriel (IRENI) and the Conseil Régional du Nord Pas-de-Calais.
No duality of interest.
References (124)
- et al.
Metabolism and bioactivation of toxicants in the lung. The in vitro cellular approach
Exp. Toxicol. Pathol.
(2005) - et al.
Expression of RALDHs (ALDH1As) and CYP26s in human tissues and during the neural differentiation of P19 embryonal carcinoma stem cell
Gene Expr. Patterns
(2008) - et al.
Expression patterns of mouse and human CYP orthologs (families 1–4) during development and in different adult tissues
Arch. Biochem. Biophys.
(2005) - et al.
cDna cloning and expression of CYP4F12, a novel human cytochrome P450
Biochem. Biophys. Res. Commun.
(2001) - et al.
A novel human cytochrome P450 4F isoform (CYP4F11): cDNA cloning, expression, and genomic structural characterization
Genomics
(2000) - et al.
Expression of xenobiotic-metabolizing CYPs in human pulmonary tissue
Exp. Toxicol. Pathol.
(1999) - et al.
Tumor-specific expression of the novel cytochrome P450 enzyme, CYP2W1
Biochem. Biophys. Res. Commun.
(2006) - et al.
Prostacyclin in human non-small cell lung cancers
Chest
(2004) - et al.
Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method
Methods
(2001) - et al.
Cytochrome P-450 mRNA expression in human liver and its relationship with enzyme activity
Arch. Biochem. Biophys.
(2001)
Characterisation of the xenobiotic-metabolizing Cytochrome P450 expression pattern in human lung tissue by immunochemical and activity determination
Toxicol. Lett.
CYP1A2 is expressed along with CYP1A1 in the human lung
Cancer Lett.
Characterisation of xenobiotic-metabolising enzyme expression in human bronchial mucosa and peripheral lung tissues
Eur. J. Cancer
Association of functionally important polymorphisms in cytochrome P4501B1 with lung cancer
Mutat. Res.
CYP2A6 genetic variation and potential consequences
Adv. Drug Deliv. Rev.
Pharmacogenetics of paclitaxel metabolism
Crit. Rev. Oncol. Hematol.
Polymorphism of selected enzymes involved in detoxification and biotransformation in relation to lung cancer
Lung Cancer
Characterization of the human lung CYP2F1 gene and identification of a novel lung-specific binding motif
J. Biol. Chem.
Molecular analysis of the CYP2F1 gene: identification of a frequent non-functional allelic variant
Mutat. Res.
CYP2S1: a short review
Toxicol. Appl. Pharmacol.
Novel extrahepatic cytochrome P450s
Toxicol. Appl. Pharmacol.
Cytochrome P450 omega hydroxylase (CYP4) function in fatty acid metabolism and metabolic diseases
Biochem. Pharmacol.
A transgenic mouse expressing human CYP4B1 in the liver
Biochem. Biophys. Res. Commun.
Alternative splicing determines the function of CYP4F3 by switching substrate specificity
J. Biol. Chem.
Cytochrome P450 4F subfamily: at the crossroads of eicosanoid and drug metabolism
Pharmacol. Ther.
Functional characterization of genetic polymorphisms identified in the human cytochrome P450 4F12 (CYP4F12) promoter region
Biochem. Pharmacol.
Conditional regulation of the human CYP4X1 and CYP4Z1 genes
Arch. Biochem. Biophys.
Bietti crystalline corneoretinal dystrophy is caused by mutations in the novel gene CYP4V2
Am. J. Hum. Genet.
Identification of a novel cytochrome P450, CYP4X1, with unique localization specific to the brain
Biochem. Biophys. Res. Commun.
CYP2U1, a novel human thymus- and brain-specific cytochrome P450, catalyzes omega- and (omega-1)-hydroxylation of fatty acids
J. Biol. Chem.
Characterization and tissue distribution of a novel human cytochrome P450-CYP2U1
Biochem. Biophys. Res. Commun.
Molecular cloning and expression of human prostacyclin synthase
Biochem. Biophys. Res. Commun.
The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis
Nat. Rev. Cancer
Molecular epidemiology of non-small cell lung cancer
Semin. Respir. Crit. Care Med.
Tumoral drug metabolism: overview and its implications for cancer therapy
J. Clin. Oncol.
mRNA distribution and heterologous expression of orphan cytochrome P450 20A1
Drug Metab. Dispos
Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues
Pharmacogenet. Genomics
Tissue distribution of mRNA expression of human cytochrome P450 isoforms assessed by high-sensitivity real-time reverse transcription PCR
Yakugaku Zasshi
Phase I and II carcinogen metabolism gene expression in human lung tissue and tumors
Clin. Cancer Res.
Expression and regulation of xenobiotic-metabolizing cytochrome P450 (CYP) enzymes in human lung
Crit. Rev. Toxicol.
Human cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone
Cancer Res.
Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2Cs
J. Biochem. Mol. Toxicol.
Characterization of microsomal cytochrome P450 enzymes involved in the oxidation of xenobiotic chemicals in human fetal liver and adult lungs
Drug Metab. Dispos.
Quantification of CYP2B7, CYP4B1, and CYPOR messenger RNAs in normal human lung and lung tumors
Cancer Res.
Expression of CYP1A1 gene in patients with lung cancer: evidence for cigarette smoke-induced gene expression in normal lung tissue and for altered gene regulation in primary pulmonary carcinomas
J. Natl. Cancer Inst.
Expression of cytochrome P450 in non-small cell lung cancer
Front. Biosci.
Specific components of prostanoid-signaling pathways are present in non-small cell lung cancer cells
Oncol. Rep.
Cytochrome P450 expression (CYP) in non-small cell lung cancer
Front. Biosci.
Expression of VDR and CYP24A1 mRNA in human tumors
Cancer Chemother. Pharmacol.
Distribution of soluble epoxide hydrolase, cytochrome P450 2C8, 2C9 and 2J2 in human malignant neoplasms
J. Mol. Histol.
Cited by (49)
Discovery of a novel potent cytochrome P450 CYP4Z1 inhibitor
2021, European Journal of Medicinal ChemistryCitation Excerpt :There is also CYP4Z1 expression in trachea but significantly lower than in the mammary gland [9]. In lung adenocarcinoma, CYP4Z1 expression is lower than in pulmonary parenchyma cells [10]. In patients with non-small-cell lung cancer (NSCLC), longer survival was observed when the CYP4Z1 gene was mutated [11].
Expression of cytochrome P450 epoxygenases and soluble epoxide hydrolase is regulated by hypolipidemic drugs in dose-dependent manner
2018, Toxicology and Applied PharmacologyCitation Excerpt :These enzymes and their EETs metabolites are probably related to the incidence and the progression of tumours as EETs are known to enhance tumour growth, increase carcinoma cell proliferation, prevent apoptosis of cancer cells and promote metastasis (Jiang et al., 2005; Jiang et al., 2007; Wei et al., 2014). As the expression of CYP epoxygenases and sEH has been described in various human tissues, including both normal healthy and tumour tissues (Bieche et al., 2007; Deloia et al., 2008; Enayetallah et al., 2006; Enayetallah et al., 2004; Leclerc et al., 2010) environmental factors may play a role in disease development and progression. In summary, fibrates, well known ligands of PPARα, regulate expression of CYP2C8, CYP2J2, and sEH at the protein level in human cell lines in concentration-dependent manner.
Human cytochrome P450 epoxygenases: Variability in expression and role in inflammation-related disorders
2014, Pharmacology and TherapeuticsCitation Excerpt :Many microsomal CYPs including the isoforms of the main human epoxygenases, i.e., CYP2Cand CYP2J2, and also other isoforms such as CYP1A1, CYP1A2, CYP2B6, CYP2E1, CYP2F1, CYP3A4, CYP3A5, CYP4B1, CYP1B1, CYP2A6, CYP2A13 and CYP2S1 have been found to be expressed in bronchial and bronchiolar epithelium, Clara cells, type II pneumocytes and alveolar macrophages (Ding & Kaminsky, 2003; Pavek & Dvorak, 2008; Leclerc et al., 2010). Furthermore, in the human larynx, mRNAs for CYP1A1, CYP2A6, CYP2B6, CYP2C, CYP2D6, CYP2E1 and CYP3A5 were detected and predominantly expressed CYPs in the trachea are CYP2A6, CYP2A13, CYP2B6 and CYP2S1 (Ding & Kaminsky, 2003; Pavek & Dvorak, 2008; Leclerc et al., 2010). Also, the CYP expression pattern was found to be slightly different in adult vs. fetal nasal mucosa.
Stabilized epoxygenated fatty acids regulate inflammation, pain, angiogenesis and cancer
2014, Progress in Lipid ResearchCitation Excerpt :However, other studies demonstrate a more complicated expression pattern of CYP epoxygenase in tumor tissues. CYP epoxygenases were underexpressed or undetectable in adenocarcinoma and squamous cell carcinoma tissues [170], breast tumor tissues [168] and renal tumor tissues [171]. The expression of sEH also varied greatly in tumor tissues [143].
1-Benzylimidazole attenuates the stemness of breast cancer cells through partially targeting CYP4Z1
2024, Environmental ToxicologyThe Association of Methylation Level in the CYP39A1 Gene with High Altitude Pulmonary Edema in the Chinese Population
2023, Pharmacogenomics and Personalized Medicine